|
|
|
01 Sep 2010 |
Aegis' ProTek(R) Excipients Prevent Aggregation and Eliminate Unwanted beta-Interferon Immunogenicity
|
3 |
|
01 Sep 2010 |
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuoIR
|
3 |
|
01 Sep 2010 |
EC Regulator Rubber-Stamps Archimedes Pharma’s Intranasal Fentanyl Spray for Cancer Pain
|
3 |
|
01 Sep 2010 |
Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
|
3 |
|
31 Aug 2010 |
Neurotech Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial for AAD-2004, a Potent Spin Trapping Molecule and Microsomal Prostaglandin E Synthase-1 Inhibitor, Targeting Alzheimer's, Parkinson's, and Lou Gehrig's Disease
|
2 |
|
31 Aug 2010 |
Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch
|
3 |
|
31 Aug 2010 |
MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone Sublingual Film for Treatment of Opioid Dependence
|
3 |
|
31 Aug 2010 |
GlaxoSmithKline (GSK), Valeant Pharmaceuticals International (VRX) Face US Delay for Epilepsy Drug, Receives New PDUFA
|
4 |
|
30 Aug 2010 |
IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product
|
3 |
|
30 Aug 2010 |
Glenmark announces the Discovery of a novel chemical entity 'GRC 17536', a potential first-in-class molecule globally
|
3 |
|
30 Aug 2010 |
Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
|
3 |
|
30 Aug 2010 |
BEMA Buprenorphine Phase 2 Study Results Selected for Presentation at Pain Week 2010
|
3 |
|
30 Aug 2010 |
Pre and Post-Operative Use of Caldolor (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
|
3 |
|
30 Aug 2010 |
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
|
3 |
|
30 Aug 2010 |
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
|
3 |
|
27 Aug 2010 |
Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
|
3 |
|
26 Aug 2010 |
Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism
|
6 |
|
26 Aug 2010 |
Alexza's Staccato Nicotine Licensed to Cypress Bioscience
|
5 |
|
25 Aug 2010 |
Addex Partner Completes ADX71149 Phase I Program
|
7 |
|
25 Aug 2010 |
Impax Pharmaceuticals Completes Enrollment in ADVANCE-PD Phase III Trial of IPX066 in Parkinson's Disease
|
6 |
|
25 Aug 2010 |
Somaxon Pharmaceuticals, Inc. (SOMX), Procter & Gamble (PG) To Launch Insomnia Drug In Sept
|
8 |
|
25 Aug 2010 |
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
|
5 |
|
23 Aug 2010 |
Alnylam and Collaborators Publish New Pre-clinical Research on Therapeutic Silencing of Parkinson's Disease Gene
|
6 |
|
23 Aug 2010 |
US FDA Panel Rejects Jazz Pharmaceuticals, Inc. (JAZZ) Drug For Fibromyalgia; Stock Falls 23.75%
|
6 |
|
20 Aug 2010 |
FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk
|
7 |
|
20 Aug 2010 |
Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta to a Broader Pain Population
|
7 |
|
19 Aug 2010 |
StemCells, Inc. Reports Breakthrough Using Human Neural Stem Cells to Restore Motor Function in Chronic Spinal Cord Injury
|
8 |
|
19 Aug 2010 |
Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain
|
7 |
|
19 Aug 2010 |
Intellect Neurosciences, Inc. Locks Database for OX1 Phase 1b Clinical Trial Intellect Neurosciences, Inc. Locks Database for OX1 Phase 1b Clinical Trial
|
8 |
|
19 Aug 2010 |
Chelsea Therapeutics Announces Initiation of Investigator-Led Phase II Study of Droxidopa in Chronic Fatigue Syndrome
|
6 |
| |
|
Results 1 - 30 of 2534 |
